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OBJECTIVE — To assess the new quantitative bone scan parameters as markers of Charcot
neuroosteoarthropathy (CNO) activity.
RESEARCH DESIGN AND METHODS — Forty-two patients with acute (n  21) and
nonacute (n  21) CNO underwent quantitative bone scanning. Patients with acute CNO were
followed for 3–12 months and bone scans were repeated after treatment. New quantitative
parameters were assessed and compared with markers of bone turnover and with skin temper-
ature difference (STD).
RESULTS — Signiﬁcant correlations between quantitative bone scan parameters and bone
turnover markers were observed (all P  0.05). These parameters decreased after treatment of
CNO, and its reduction to the baseline value correlated with differences of bone turnover
markers and STD (all P  0.05).
CONCLUSIONS — Our study suggests that bone scanning can be used not only for diag-
nosis of CNO but also for monitoring disease activity by quantitative bone scan parameters.
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E
arly morphological diagnosis and
evaluation of disease activity play an
importantroleinthemanagementof
Charcot neuroosteoarthropathy (CNO)
(1–4). In clinical practice, morphological
methods(e.g.,plainX-rays,computedto-
mography, magnetic resonance) are use-
ful for anatomical and bone structure
information (5); and skin temperature
difference (STD) is used for the diagnosis
and monitoring of the progression of
CNO(4,6).However,theyarenotspeciﬁc
to the bone-remodelling process and
could provide less precise assessment in
patientswithbilateralCNO,whichisseen
in22%ofpatientswithCNO(7).Theaim
of our study was to deﬁne new quantita-
tive bone scan parameters for the as-
sessment of CNO activity in relation to
morphological and functional factors.
RESEARCH DESIGN AND
METHODS— Forty-two diabetic pa-
tients from the foot clinic with unilateral
CNO,inwhombonescanswereperformed
during a 3-year period, were enrolled into
the study. The study was approved by the
local ethics committee, and all participants
gave written informed consent.
Patientswithacute(n21)andnon-
acute (n  21) CNO had a bone scan at
baseline,andtheformerwerefollowedup
until quiescence, when repeat scans were
performedaftertreatmentinthenonacute
phase (deﬁned as a reduction of clinical
signs [e.g., edema, redness] and STD
[temperature difference between the site
ofmaximumdeformityandsimilarsiteon
the contralateral foot] below 2°C). Quan-
titative bone scan parameters, markers of
bone turnover (COOH-terminal telopep-
tide region of type 1 collagen [1CTP] and
bone-speciﬁc isoenzyme of alkaline phos-
phatase [BALP]) and measurement of STD
were used for determination of CNO ac-
tivityinallpatientsatthebeginningofthe
study. All tests were repeated in the sub-
group of patients with acute CNO in the
follow-up study when STD decreased be-
low 2°C (mean 24.6  6.8 weeks after
treatment).
Quantitative bone scintigraphy was
performed following intravenous injec-
tion of 740 MBq of technetium-99m
methylenediphosphonate. Radionuclide
examinations were recorded by a gamma
camera and computer system (DST-XL;
Sopha Medical Vision International, Buc,
France).
Thequantitativeparameterswerecal-
culated by using the following formulas:
FWB 
CF  100
CWB
where FWB, ratio of foot and whole-body
uptake of isotope; CF, count of detected
impulses over the affected foot; and CWB,
countofdetectedimpulsesoverthewhole
body (count of impulses over the urinary
bladder were excluded);
BFV (cm/s) 
DBF(cm)
TF  TB(s)
where BFV, blood ﬂow velocity (speed of
isotopeﬂowfromaorticbifurcationtothe
affected foot); DBF, distance between aor-
tic bifurcation and ankle; TF, time of ac-
tivity onset in the ankle region; and TB,
time of activity onset in the aortic
bifurcation.
1CTP and BALP were measured by
radioimmunoassay (Telopeptide 1CTP
[
125I] Kit, Orion Diagnostica, Espoo, Fin-
land; and BALP kit, Tandem-R Ostase,
Beckman Coulter, Fullerton, CA). STD
was assessed by an infrared thermometer
(Sherwood Medical Company, St. Louis,
MO) after a 30-min rest (8).
Results were expressed as means 
SD. Statistical analysis was performed us-
ing GraphPad Prism version 5.00 for
Windows (GraphPad Software, San Di-
ego,CA).Correlationwasassessedbylin-
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correlation coefﬁcient. A P value 0.05
was considered signiﬁcant.
RESULTS— Patients with acute and
nonacuteCNOwerematchedforage,sex,
duration of diabetes, and glycemic con-
trol (Table 1). Patients with acute CNO
had signiﬁcantly increased parameters of
disease activity in comparison with pa-
tients with nonacute CNO (Table 1).
In the whole cohort at baseline, sig-
niﬁcant correlations were observed be-
tweenFWBandmarkersofboneturnover
(1CTP, BALP: P  0.0001 and  0.0004,
respectively), but correlation with STD
was not signiﬁcant. BFV signiﬁcantly cor-
related with 1CTP, BALP, and STD (P 
0.002,0.03,and0.02,respectively).
However, only in patients with acute
CNO did STD correlate with FWB and
BFV (P  0.01).
In addition, there were signiﬁcant re-
ductions in bone scan parameters, bone
turnover markers, and STD after treat-
ment of acute CNO (Table 1). There were
also signiﬁcant correlations between
changes from baseline between FWB and
1CTP (P  0.002), BALP (P  0.005),
and STD (P  0.02). Similar correlations
were also seen for BFV (all P  0.05).
CONCLUSIONS — In this study, we
have shown that our new quantitative
bonescanparameters,FWBandBFV,sig-
niﬁcantly correlated with bone turnover
markers in patients with CNO; but only
BFValsocorrelatedwithSTDinthewhole
cohort. In patients with acute CNO, we
observed signiﬁcant reduction in bone
scan parameters, which correlated with
changes in bone turnover markers and
STD after treatment.
In a previous study, correlation be-
tweenSTDandtheratioofisotopeuptake
of the affected and unaffected foot was
seen, but correlation between STD and
the ratio of isotope uptake of affected foot
and ipsilateral tibia was not signiﬁcant
(9). We felt that using the whole-body
activitywouldbeabetterparameterasthe
bones in the affected leg could have in-
creased uptake due to increased blood
ﬂow to that leg secondary to the Charcot
process, which could explain why the
above study did not show any difference.
However,measuringFWBisindependent
of blood ﬂow to the ipsilateral leg. In ad-
dition, we have shown a direct relation-
ship between FWB and the bone-
remodelling process assessed by 1CTP
and BALP. Similar results for BFV were
alsoseen,butthisparameterisdependent
on vascular reactivity, which could be in-
ﬂuenced by other factors (e.g., foot
infection).
STD was shown to correlate with
bone scan parameters (FWB and BFV) at
baseline and follow-up in acute CNO.
Therefore, STD can be helpful as a bed-
side clinical indicator of disease activity.
However, when the diagnosis is unclear,
bone-scanning parameters can be used as
an adjunct to diagnosis and monitoring
treatment but also in patients with bilat-
eral CNO during follow-up when STD
may not be helpful.
There are some limitations to quanti-
tative bone scanning. First, it may not be
speciﬁc for the diagnosis of CNO; it is
dependent on strict observance of stan-
dard reference conditions during exami-
nation. Finally, repeated bone scans
would increase radiation exposure but
also have cost implications.
Inconclusion,ourstudypointstothe
potentialutilityofquantitativebonescan-
ning for diagnosis but probably more im-
portantly for CNO activity monitoring.
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Table 1—Baseline and follow-up demographics and biochemical and radiological parameters
in patients with acute and nonacute CNO
Nonacute CNO Acute CNO Follow-up*
n 21 21 21
Age (years) 52.33  10.63 54.29  9.64 —
Sex (M/F) 12/9 13/8 —
Duration of diabetes (years) 17.10  7.52 19.81  10.06 —
Type 2 diabetes 14 (66.7) 14 (66.7) —
VPT (V) 43.67  7.73 44.48  8.17 —
A1C (%) 8.58  1.99 8.36  1.55 8.21  1.57
1CTP (g/l) 6.95  2.32† 9.57  4.16 7.61  3.55§
BALP (g/l) 11.22  2.66† 15.23  7.90 10.82  6.71§
STD (°C) 1.17  0.46‡ 3.15  1.22 1.09  0.48§
BFV (m/s) 9.33  3.10† 11.54  3.70 8.11  2.51§
FWB 3.30  1.44† 5.20  2.86 2.67  1.12§
Data are means  SD or n (%) unless otherwise indicated. *Mean follow-up of acute CNO was 24.6  6.8
weeks after treatment. Acute versus nonacute CNO: †P  0.05, ‡P  0.001. Acute versus follow-up group:
§P  0.001. VPT, vibration perception threshold.
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